ties are found in about 5-6 births per 1000.-Congenital malformations such as spina bifida (two to eight per 1000 births) and congenital heart disease (six to eight per 1000 births) are more common still, but in these cases the genetic component is only partial, with the balance coming from environmental influences.
Finally, four common disorders-schizophrenia, manic of substantial size; in either case the effect is enough to change the gene map sufficiently to make the diagnosis plain. In most cases, however, those approaches do not lead to recognition of the abnormality-only a handful of the 300 abnormal haemoglobin genes can be pinpointed directly by restriction enzymes. For the remainder, the answer seems likely to come from two difficult concepts-linkage and polymorphism. These are defined as follows. Linkage is the term used when the gene under study is found to be positioned very close to another gene which can be easily identified-for example, the associations between HLA antigens and genetic susceptibility to disease. Polymorphisms depend on the fact that many mutations alter the length of the fragments produced by restriction enzymes but have no other apparent effect. These neutral mutations produce variations-polymorphisms-in the fragment length produced by restriction enzyme analysis of the DNA in the normal population. If an identifiable change in the fragment lengths can be shown to be linked with an abnormal gene, then the two should be transmitted together genetically. Analysis of families with some members affected by the illness caused by the gene should then show whether the presence of the gene can be diagnosed by use of variation in the restriction enzyme fragment lengths.
Professor Weatherall warns that the establishment of linkages between fragment length polymorphisms and important medical genes is not going to be easy and that this diagnostic method seems unlikely to be very helpful in screening for carriers. Nevertheless he sees grounds for cautious optimism. He estimates that there may be around 10 million single-site restriction fragment length polymorphisms in the whole human genome, and there may be many highly variable regions which would allow linkage analysis in individual families.
Where is the new genetics leading us ? For the time being the main practical application is in prenatal diagnosis. Already the diagnosis of Down's syndrome, thalassaemia, and several other blood disorders has become an established part of clinical obstetrics-but obstetricians have to wait until well into the midtrimester before they can carry out procedures such as amniocentesis and fetoscopy and so obtain the cells or blood required. Recently, however, techniques developed in the USSR have been used to sample the trophoblast layer of the embryo at eight to 10 weeks' gestation. Professor Robert Williamson at St Mary's Hospital, London, has shown that enough DNA may be obtained in this way for direct analysis of the genes, so making possible the diagnosis of some haemoglobinopathies. Since, however, only a few haemoglobinopathies cause mutations directly identifiable by restriction enzymes this approach will be of limited value until more use can be made of restriction enzyme fragment length polymorphism. In most cases establishment of linkage between the abnormal gene and a specific polymorphism will depend on analysis of individual members of the family concerned. Ideally families should be examined at leisure-a time consuming and expensive undertaking.
Prenatal diagnosis and selective abortion may reduce the load of genetic disorders but they are surely, 
